Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26360850 | 0.91 | DRD2 (0.40) | CD274SMN1; SMN2MAPK1DRD2L3MBTL1 | |
| SCHEMBL22009237 | 0.86 | CXCR4 (0.39) | SMN1; SMN2MAPK1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL31721094 | 0.86 | BRD4 (0.44) | DRD2BCHEACHE | |
| SCHEMBL22009251 | 0.80 | CYP17A1 (0.42) | DRD2F10 | |
| SCHEMBL26908058 | 0.80 | BCHE (0.41) | CD274SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL24454240 | 0.80 | CYP17A1 (0.38) | SMN1; SMN2DRD2NPC1RAB9ATP53 | |
| SCHEMBL22009250 | 0.80 | CYP17A1 (0.46) | DRD2F10 | |
| SCHEMBL22009252 | 0.79 | CYP17A1 (0.41) | DRD2F10 | |
| SCHEMBL29672670 | 0.78 | CD274 (0.41) | CD274SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL24418305 | 0.78 | CD274 (0.41) | CD274SMN1; SMN2MAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185803-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220177461-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200157087-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185803-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CD274 201/4885SMN1; SMN2 1817/4885MAPK1 3312/4885 |
| US-20200157087-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CD274 201/4885SMN1; SMN2 1817/4885MAPK1 3312/4885 |
| US-20220177461-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CD274 201/4885SMN1; SMN2 1817/4885MAPK1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.